Please Wait
Applying Filters...
menu
    • menu
    Evonik

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Zurletrectinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Innocare Approves Next-Gen TRK Inhibitor Zurletrectinib In China
    Innocare Approves Next-Gen TRK Inhibitor Zurletrectinib In China

    11 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/11/3203741/0/en/InnoCare-Announces-Approval-of-the-Next-Generation-TRK-Inhibitor-Zurletrectinib-in-China.html

    GLOBENEWSWIRE
    11 Dec 2025
    Share Share
    InnoCare's Zurletrectinib Gets Priority Review from China's NMPA
    InnoCare's Zurletrectinib Gets Priority Review from China's NMPA

    01 May 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250501565030/en/InnoCares-Zurletrectinib-Receives-Priority-Review-from-Chinas-NMPA

    BUSINESSWIRE
    01 May 2025
    Share Share
    InnoCare Announces Acceptance of NDA for Zurletrectinib in China
    InnoCare Announces Acceptance of NDA for Zurletrectinib in China

    16 Apr 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250415365931/en/InnoCare-Announces-the-Acceptance-of-New-Drug-Application-for-pan-TRK-Inhibitor-Zurletrectinib-in-China

    BUSINESSWIRE
    16 Apr 2025
    Share Share
    Zurletrectinib Shows Strong Activity Against NTRK Fusion-Positive Tumors
    Zurletrectinib Shows Strong Activity Against NTRK Fusion-Positive Tumors

    30 Jul 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240730463296/en

    BUSINESSWIRE
    30 Jul 2024
    Share Share
    InnoCare Announces First Pediatric Patient Dosed in Trial of Zurletrectinib
    InnoCare Announces First Pediatric Patient Dosed in Trial of Zurletrectinib

    23 Jan 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240123487367/en

    BUSINESSWIRE
    23 Jan 2024
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.